Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen’s business strategy is the realisation of value via licensing transactions – validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.
Type
Public
HQ
Southampton, GB
Size (employees)
12 (est)-7%
Synairgen is headquartered in Southampton, GB

Synairgen Office Locations

Synairgen has an office in Southampton
Southampton, GB (HQ)
Mailpoint 810 Southampton General Hospital Tremona Road

Synairgen Data and Metrics

Synairgen Financial Metrics

Synairgen's revenue was reported to be £25 k in FY, 2015
GBP

Net income (FY, 2016)

(2.8 m)

Market capitalization (24-Jul-2017)

7.8 m

Closing share price (24-Jul-2017)

0.1

Cash (31-Dec-2016)

3.1 m
Synairgen's current market capitalization is £7.8 m.
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

4.3 m25 k

Revenue growth, %

(99%)

Pre tax profit

(2.3 m)1.1 m(2.6 m)(3.4 m)

Net Income

(2 m)1.2 m(2.3 m)(2.8 m)
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash

1.3 m9.6 m4 m3.1 m

Current Assets

1.7 m9.8 m8.2 m5.5 m

PP&E

15 k17 k17 k13 k

Goodwill

297 k102 k81 k62 k

Total Assets

2 m9.9 m8.3 m5.5 m

Accounts Payable

20 k78 k281 k356 k

Current Liabilities

457 k495 k936 k860 k

Total Liabilities

457 k495 k936 k860 k

Retained Earnings

(2 m)1.2 m(2.3 m)(2.8 m)

Total Equity

1.6 m9.4 m7.3 m4.7 m

Financial Leverage

1.3 x1.1 x1.1 x1.2 x
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(1.8 m)1.8 m(1.9 m)(3 m)

Cash From Financing Activities

6.5 m1 k

Income Taxes Paid

224 k63 k304 k587 k
Y, 2016

Financial Leverage

1.2 x

Synairgen Market Value History

Synairgen Online and Social Media Presence

Synairgen Company Life and Culture

You may also be interested in